WORLD ASTHMA DAY

 


Sundyota Numandis specializes in offering superior, clinically proven and safer therapies from non-synthetic origins. Our exclusive range of probiotics, nutraceuticals and phytopharmaceuticals extends across several therapeutic categories. This World Asthma Day, we offer a strain-specific probiotic and a nutraceutical product that supports respiratory health.

World Asthma Day is organized by the Global Initiative for Asthma, (GINA) a World Health Organization collaborative organization founded in 1993. 

WHO recognizes asthma as a major public health issue. As per a global estimate by WHO in 2016, more than 339 million people had Asthma and there were 417,918 deaths due to asthma. Among India's 1.31 billion people, about 6% of children and 2% of adults have asthma.

In recent years, a lot of research has happened in the field of probiotics and nutraceuticals. The research has proved the definite role of strain-specific probiotics and nutraceuticals in the management of asthma.  Strain-specific probiotics and nutraceuticals act on molecular targets that are unaddressed by conventional therapies. These properties make strain-specific probiotics and nutraceuticals complement conventional drug therapies. Further, such therapies are safe for long-term use. Sundyota Numandis Group of Companies specializes in researching and offering exclusive strain-specific probiotics and nutraceuticals. For respiratory health, we have.

AAP-2:

A patented combination of bacterial probiotics that works on the root cause of allergies; by modulating Th-0 cell activity. Reduces IgE and improves C-ACT and PEFR in allergic asthma

Alviolife:

A patented nutraceutical blend for healthy breathing. Reduces inflammation and improves FEV1 & PEFR in asthma patients

Being committed to better human healthcare through superior and safer therapies, Sundyota Numandis relentlessly work to research and offer such products. We also share our products with like-minded organizations, to spread their goodness to more and more patients.

Comments

Popular Posts